Eli Lilly just gave investors several reasons to cheer.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Novo Nordisk's CagriSema, a combination drug for weight loss, matches Lilly's Zepbound in late-stage trial, but doesn't surpass it. Stock falls 19% on news.

Eli Lilly stock is trending lower in December, but an FDA decision will keep compounders from making tirzepatide. Is Lilly stock a buy? Novo Nordisk stock fell sharply early Friday after the ...